Verrica Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $14,344 | $12,702 | $3,439 | $344 |
Gross Profit | 13,235 | 12,362 | 3,016 | -281 |
EBITDA | 2,004 | 2,534 | -7,331 | -13,600 |
EBIT | 1,820 | 2,335 | -7,539 | -13,853 |
Net Income | -274 | 204 | -9,742 | -16,202 |
Net Change In Cash | 14,344 | 12,702 | 3,439 | 344 |
Free Cash Flow | 9,685 | -10,044 | -12,677 | -16,064 |
Cash | 21,097 | 15,396 | 29,595 | 46,329 |
Basic Shares | 9,490 | 9,490 | 9,483 | 6,732 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $7,566 | $5,124 | $9,032 | $12,000 |
Gross Profit | 4,826 | 4,378 | 8,307 | 11,528 |
EBITDA | -65,898 | -62,197 | -21,597 | -30,313 |
EBIT | -67,167 | -63,033 | -22,315 | -30,785 |
Net Income | -76,579 | -66,995 | -24,487 | -35,080 |
Net Change In Cash | 7,566 | 5,124 | 9,032 | 12,000 |
Cost of Revenue | 18,521 | 5,066 | ||
Free Cash Flow | -60,954 | -38,939 | -18,952 | -28,465 |
Cash | 46,329 | 69,547 | 34,273 | 15,752 |
Basic Shares | 5,180 | 4,534 | 3,416 | 2,704 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0.13 |
2025-06-30 | $0.02 |
2025-03-31 | -$0.10 |
2024-12-31 | -$0.20 |
